CN113797341A - Atr抑制剂和parp1抑制剂联用在制备治疗乙肝相关性肝癌的药物中的用途 - Google Patents
Atr抑制剂和parp1抑制剂联用在制备治疗乙肝相关性肝癌的药物中的用途 Download PDFInfo
- Publication number
- CN113797341A CN113797341A CN202010536991.0A CN202010536991A CN113797341A CN 113797341 A CN113797341 A CN 113797341A CN 202010536991 A CN202010536991 A CN 202010536991A CN 113797341 A CN113797341 A CN 113797341A
- Authority
- CN
- China
- Prior art keywords
- inhibitor
- atr
- parp1
- liver cancer
- related liver
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 239000003112 inhibitor Substances 0.000 title claims abstract description 126
- 108010064218 Poly (ADP-Ribose) Polymerase-1 Proteins 0.000 title claims abstract description 67
- 208000014018 liver neoplasm Diseases 0.000 title claims abstract description 53
- 201000007270 liver cancer Diseases 0.000 title claims abstract description 52
- 208000002672 hepatitis B Diseases 0.000 title claims abstract description 30
- 239000003814 drug Substances 0.000 title claims abstract description 16
- 102000015087 Poly (ADP-Ribose) Polymerase-1 Human genes 0.000 title claims abstract 17
- 238000002360 preparation method Methods 0.000 title claims description 8
- 206010028980 Neoplasm Diseases 0.000 title description 51
- 229940079593 drug Drugs 0.000 title description 6
- 230000002238 attenuated effect Effects 0.000 title description 3
- OHUHVTCQTUDPIJ-JYCIKRDWSA-N ceralasertib Chemical group C[C@@H]1COCCN1C1=CC(C2(CC2)[S@](C)(=N)=O)=NC(C=2C=3C=CNC=3N=CC=2)=N1 OHUHVTCQTUDPIJ-JYCIKRDWSA-N 0.000 claims description 21
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 238000000034 method Methods 0.000 claims description 7
- 239000004480 active ingredient Substances 0.000 claims description 2
- 239000003937 drug carrier Substances 0.000 claims description 2
- 239000004615 ingredient Substances 0.000 claims description 2
- 239000000463 material Substances 0.000 claims description 2
- 208000006454 hepatitis Diseases 0.000 claims 1
- 231100000283 hepatitis Toxicity 0.000 claims 1
- 230000004614 tumor growth Effects 0.000 abstract description 8
- 230000002195 synergetic effect Effects 0.000 abstract description 6
- 102100023712 Poly [ADP-ribose] polymerase 1 Human genes 0.000 description 50
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 24
- 241000699670 Mus sp. Species 0.000 description 20
- 239000003981 vehicle Substances 0.000 description 18
- 238000002474 experimental method Methods 0.000 description 15
- 230000000694 effects Effects 0.000 description 13
- 241001465754 Metazoa Species 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 10
- DNIAPMSPPWPWGF-UHFFFAOYSA-N propylene glycol Substances CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 10
- 239000002904 solvent Substances 0.000 description 10
- 230000005764 inhibitory process Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 230000037396 body weight Effects 0.000 description 6
- 201000011510 cancer Diseases 0.000 description 6
- 230000008859 change Effects 0.000 description 6
- 210000001519 tissue Anatomy 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 5
- 230000005778 DNA damage Effects 0.000 description 4
- 231100000277 DNA damage Toxicity 0.000 description 4
- 230000002159 abnormal effect Effects 0.000 description 4
- 230000000857 drug effect Effects 0.000 description 4
- 238000007912 intraperitoneal administration Methods 0.000 description 4
- 239000007928 intraperitoneal injection Substances 0.000 description 4
- 230000037361 pathway Effects 0.000 description 4
- 238000007619 statistical method Methods 0.000 description 4
- 208000024891 symptom Diseases 0.000 description 4
- 210000004881 tumor cell Anatomy 0.000 description 4
- 229920000776 Poly(Adenosine diphosphate-ribose) polymerase Polymers 0.000 description 3
- 108091035539 telomere Proteins 0.000 description 3
- 210000003411 telomere Anatomy 0.000 description 3
- 102000055501 telomere Human genes 0.000 description 3
- 208000035943 Aphagia Diseases 0.000 description 2
- 206010003445 Ascites Diseases 0.000 description 2
- 206010006100 Bradykinesia Diseases 0.000 description 2
- 230000005971 DNA damage repair Effects 0.000 description 2
- 206010012735 Diarrhoea Diseases 0.000 description 2
- 208000000059 Dyspnea Diseases 0.000 description 2
- 206010013975 Dyspnoeas Diseases 0.000 description 2
- 208000006083 Hypokinesia Diseases 0.000 description 2
- 206010021113 Hypothermia Diseases 0.000 description 2
- 206010028289 Muscle atrophy Diseases 0.000 description 2
- 206010033799 Paralysis Diseases 0.000 description 2
- 208000005392 Spasm Diseases 0.000 description 2
- 240000004922 Vigna radiata Species 0.000 description 2
- 235000010721 Vigna radiata var radiata Nutrition 0.000 description 2
- 235000011469 Vigna radiata var sublobata Nutrition 0.000 description 2
- 230000003187 abdominal effect Effects 0.000 description 2
- 230000003321 amplification Effects 0.000 description 2
- 238000010171 animal model Methods 0.000 description 2
- 230000000740 bleeding effect Effects 0.000 description 2
- 230000022131 cell cycle Effects 0.000 description 2
- 238000010276 construction Methods 0.000 description 2
- 230000034994 death Effects 0.000 description 2
- 231100000517 death Toxicity 0.000 description 2
- 230000035622 drinking Effects 0.000 description 2
- 238000011156 evaluation Methods 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000012631 food intake Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000002631 hypothermal effect Effects 0.000 description 2
- 238000010832 independent-sample T-test Methods 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- 230000020763 muscle atrophy Effects 0.000 description 2
- 201000000585 muscular atrophy Diseases 0.000 description 2
- 230000007935 neutral effect Effects 0.000 description 2
- 238000003199 nucleic acid amplification method Methods 0.000 description 2
- 230000003285 pharmacodynamic effect Effects 0.000 description 2
- 238000004321 preservation Methods 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000000750 progressive effect Effects 0.000 description 2
- 230000002035 prolonged effect Effects 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 238000011160 research Methods 0.000 description 2
- 230000001225 therapeutic effect Effects 0.000 description 2
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 2
- 230000003442 weekly effect Effects 0.000 description 2
- 230000004580 weight loss Effects 0.000 description 2
- ZKHQWZAMYRWXGA-KQYNXXCUSA-J ATP(4-) Chemical compound C1=NC=2C(N)=NC=NC=2N1[C@@H]1O[C@H](COP([O-])(=O)OP([O-])(=O)OP([O-])([O-])=O)[C@@H](O)[C@H]1O ZKHQWZAMYRWXGA-KQYNXXCUSA-J 0.000 description 1
- ZKHQWZAMYRWXGA-UHFFFAOYSA-N Adenosine triphosphate Natural products C1=NC=2C(N)=NC=NC=2N1C1OC(COP(O)(=O)OP(O)(=O)OP(O)(O)=O)C(O)C1O ZKHQWZAMYRWXGA-UHFFFAOYSA-N 0.000 description 1
- 206010006187 Breast cancer Diseases 0.000 description 1
- 208000026310 Breast neoplasm Diseases 0.000 description 1
- 102000053642 Catalytic RNA Human genes 0.000 description 1
- 108090000994 Catalytic RNA Proteins 0.000 description 1
- 102100025064 Cellular tumor antigen p53 Human genes 0.000 description 1
- 208000037051 Chromosomal Instability Diseases 0.000 description 1
- 102100034533 Histone H2AX Human genes 0.000 description 1
- 101000721661 Homo sapiens Cellular tumor antigen p53 Proteins 0.000 description 1
- 101001067891 Homo sapiens Histone H2AX Proteins 0.000 description 1
- 101001095095 Homo sapiens Proline-rich acidic protein 1 Proteins 0.000 description 1
- 101000785063 Homo sapiens Serine-protein kinase ATM Proteins 0.000 description 1
- 101000777293 Homo sapiens Serine/threonine-protein kinase Chk1 Proteins 0.000 description 1
- 101000777277 Homo sapiens Serine/threonine-protein kinase Chk2 Proteins 0.000 description 1
- 206010064912 Malignant transformation Diseases 0.000 description 1
- 102100037034 Proline-rich acidic protein 1 Human genes 0.000 description 1
- 102100020824 Serine-protein kinase ATM Human genes 0.000 description 1
- 102100031081 Serine/threonine-protein kinase Chk1 Human genes 0.000 description 1
- 102100031075 Serine/threonine-protein kinase Chk2 Human genes 0.000 description 1
- 102100029538 Structural maintenance of chromosomes protein 1A Human genes 0.000 description 1
- 239000002246 antineoplastic agent Substances 0.000 description 1
- 229940041181 antineoplastic drug Drugs 0.000 description 1
- 230000030833 cell death Effects 0.000 description 1
- 230000001419 dependent effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 230000036212 malign transformation Effects 0.000 description 1
- 230000036210 malignancy Effects 0.000 description 1
- 239000000203 mixture Substances 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000000865 phosphorylative effect Effects 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- 239000002994 raw material Substances 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 230000008844 regulatory mechanism Effects 0.000 description 1
- 230000008439 repair process Effects 0.000 description 1
- 108091092562 ribozyme Proteins 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 238000009097 single-agent therapy Methods 0.000 description 1
- 108010004731 structural maintenance of chromosome protein 1 Proteins 0.000 description 1
- 238000006467 substitution reaction Methods 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/5375—1,4-Oxazines, e.g. morpholine
- A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
- A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
- A61K31/5517—1,4-Benzodiazepines, e.g. diazepam or clozapine condensed with five-membered rings having nitrogen as a ring hetero atom, e.g. imidazobenzodiazepines, triazolam
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Virology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biotechnology (AREA)
- Molecular Biology (AREA)
- Gastroenterology & Hepatology (AREA)
- Communicable Diseases (AREA)
- Oncology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
本发明提供了ATR抑制剂和PARP1抑制剂联用在制备治疗乙肝相关性肝癌的药物中的用途,属于制药领域。ATR抑制剂和PARP1抑制剂联合使用能够有效抑制乙肝相关性肝癌的肿瘤组织生长,可有效治疗乙肝相关性肝癌;且联合使用ATR抑制剂和PARP1抑制剂对乙肝相关性肝癌具有协同增效的作用,可用于制备治疗乙肝相关性肝癌的药物,具有良好的前景。
Description
技术领域
本发明属于制药领域,具体涉及ATR抑制剂和PARP1抑制剂联用在制备治疗乙肝相关性肝癌的药物中的用途。
背景技术
ATR(ataxia-telangiectasia mutated and rad3-related)作为DNA损伤感受器,是DNA损伤通路的关键分子。在获得DNA损伤信号后,ATR发生过度活化,通过磷酸化下游关键分子CHK1、SMC1、CHK2、H2AX、p53等激活多条信号通路,启动应激系统,调节细胞周期各个检验点,引起细胞周期阻滞,影响染色体稳定性,最终可能导致细胞恶性转化。因此DNA损伤时,ATR通路的过度活化可能在恶性肿瘤的发生发展中起重要作用。研究表明,抑制ATR可以选择性的抑制肿瘤细胞,且对正常细胞干扰较少,因此ATR有望成为高选择性抗肿瘤药物的靶标,目前ATR抑制剂受到越来越多的关注,ATR抑制剂可诱导ATR通路依赖型恶性肿瘤细胞死亡,用于癌症治疗有很大潜力。
聚腺苷二磷酸核糖聚合酶(PARP)是一种与DNA损伤修复密切相关的核酶,其中PARP1亚型承担了90%以上的修复任务。在肿瘤细胞中DNA损伤修复通路异常活跃。PARP1是一个多受体的蛋白质,可启动细胞内对端粒结构变化作出反应的信号转导机制,维持癌变细胞端粒结构的稳定,在癌细胞端粒结构的调控机制中有重要作用。抑制PARP1的活性可以抑制肿瘤的生长。近年来,已经有多个PARP1抑制剂进入临床研究阶段,PARP1抑制剂已经成为肿瘤药物研发热点之一。
ATR抑制剂和PARP1抑制剂均可用于部分癌症的治疗,还有研究利用PARP1抑制剂与ATR抑制剂药物联用治疗乳腺癌,提高治疗效果。但是癌症治疗机理是十分复杂的,尚未见利用PARP1抑制剂与ATR抑制剂药物联用治疗乙肝相关性肝癌。
发明内容
本发明的目的是提供ATR抑制剂和PARP1抑制剂联用在制备治疗乙肝相关性肝癌的药物中的用途。
本发明提供了ATR抑制剂和PARP1抑制剂联用在制备治疗乙肝相关性肝癌的药物中的用途。
进一步地,所述ATR抑制剂和PARP1抑制剂的重量配比为(5~20):3;
优选地,所述ATR抑制剂和PARP1抑制剂的重量配比为10:3。
进一步地,所述ATR抑制剂为AZD6738;所述PARP1抑制剂为AG14361。
AZD6738:别名为Ceralasertib,CAS 1352226-88-0,分子式C20H24N6O2S,分子量为412.51,是一种ATR抑制剂,其结构式如下:
AG14361:CAS 328543-09-5,分子式C19H20N4O,分子量为320.39,是一种PARP1抑制剂,其结构式如下:
本发明还提供了一种治疗乙肝相关性肝癌的药物组合物,它是由ATR抑制剂和PARP1抑制剂组成。
进一步地,所述ATR抑制剂和PARP1抑制剂的重量配比为(5~20):3;
优选地,所述ATR抑制剂和PARP1抑制剂的重量配比为10:3。
进一步地,所述ATR抑制剂为AZD6738;所述PARP1抑制剂为AG14361。
本发明提供了一种前述的药物组合物的制备方法,所述方法是按照以下步骤制备:按照重量配比取ATR抑制剂和PARP1抑制剂,混合,即可。
本发明提供了一种治疗乙肝相关性肝癌的药物制剂,它是由前述的药物组合物为活性成分,加上药学上可接受的辅料或者辅助性成分制备而成的制剂。
本发明提供了一种治疗乙肝相关性肝癌的联合用药,它含有相同或者不同规格的同时或者分别给药的ATR抑制剂和PARP1抑制剂,以及药学上可接受的载体;所述ATR抑制剂和PARP1抑制剂的重量配比为(5~20):3;
优选地,所述ATR抑制剂和PARP1抑制剂的重量配比为10:3。
进一步地,所述ATR抑制剂为AZD6738;所述PARP1抑制剂为AG14361。
本发明实施例中ATR抑制剂为AZD6738,PARP1抑制剂为AG14361。但ATR抑制剂和PARP1抑制剂不仅仅限制于这两种种类,其他ATR抑制剂和PARP1抑制剂按照本发明所述方法,都可以达到相应疗效。
ATR抑制剂和PARP1抑制剂联合使用仅仅对HBV阳性肝癌,即对乙肝相关性肝癌具有协同增效作用,对于非乙肝相关性肝癌具无协同增效的作用。
ATR抑制剂和PARP1抑制剂联合使用能够有效抑制乙肝相关性肝癌的肿瘤组织生长,可有效治疗乙肝相关性肝癌;且联合使用ATR抑制剂和PARP1抑制剂对乙肝相关性肝癌具有协同增效的作用,可用于制备治疗乙肝相关性肝癌的药物,具有良好的前景。
显然,根据本发明的上述内容,按照本领域的普通技术知识和惯用手段,在不脱离本发明上述基本技术思想前提下,还可以做出其它多种形式的修改、替换或变更。
以下通过实施例形式的具体实施方式,对本发明的上述内容再作进一步的详细说明。但不应将此理解为本发明上述主题的范围仅限于以下的实例。凡基于本发明上述内容所实现的技术均属于本发明的范围。
附图说明
图1为利用HBV阳性肝癌PDX模型评估ATR抑制剂联合PARP1抑制剂疗效的结果:A为给药28天后,各组肿瘤实体图;B为各组随时间增加肿瘤的体积变化;C为各组随时间增加荷瘤鼠的重量变化;D为给药28天后,各组肿瘤的重量。
图2为利用HBV阴性肝癌PDX模型评估ATR抑制剂联合PARP1抑制剂疗效的结果:A给药14天后,为各组肿瘤实体图;B为各组随时间增加肿瘤的体积变化;C为各组随时间增加荷瘤鼠的重量变化。
具体实施方式
本发明具体实施方式中使用的原料、设备均为已知产品,通过购买市售产品获得。
实施例1、利用HBV阳性肝癌PDX模型评估ATR抑制剂联合PARP1抑制剂的疗效
1、实验方法
(1)HBV阳性肝癌PDX模型的构造方法:建立肝癌PDX模型通过华西医院伦理委员会批准,选择HBV阳性肝癌组织,剪碎成绿豆大小,1小时内接种于NCG小鼠皮下,当肿瘤体积达到500mm3时,再次扩增传代至开展药效实验。
(2)药物评价方法:
按药效实验需要,接种肿瘤组织至相应数量的NCG小鼠,当肿瘤体积平均值达到100mm3左右时,按照统计学方法进行随机分组,每组入组7只荷瘤鼠。具体分组及给药方法如下:
组别G1(溶剂对照组):荷瘤鼠只数为7只,同时给药溶媒1和溶媒2。溶媒1和溶媒2的给药体积分别100μL/只,给药方式为灌胃给药(i.g.)。
组别G2:荷瘤鼠只数为7只,给药ATR抑制剂AZD6738。将AZD6738溶于溶媒1中,AZD6738的给药剂量为50mg/kg,给药体积为100μL/只,给药方式为灌胃给药(i.g.)。
组别G3:荷瘤鼠只数为7只,ATR抑制剂AZD6738和PARP1抑制剂AG14361联合给药。将AZD6738溶于溶媒1中,AG14361溶于溶媒2中:AZD6738的给药剂量为50mg/kg,给药体积为100μL/只,给药方式为灌胃给药(i.g.);AG14361的给药剂量为15mg/kg,给药体积为100μL/只,给药方式为腹腔注射(i.p.)。
组别G4:荷瘤鼠只数为7只,给药PARP1抑制剂AG14361。将AG14361溶于溶媒2中,AG14361的给药剂量为15mg/kg,给药体积为100μL/只,给药方式为腹腔注射(i.p.)。
溶媒1:含二甲亚砜(DMSO)和丙二醇的ddH2O,其中二甲亚砜浓度为10%,丙二醇浓度为40%;溶媒2:含二甲亚砜(DMSO)的ddH2O,其中二甲亚砜浓度为4%;溶媒1和溶媒2配制好后均置于-80℃保存。
所有组给药频率为1次/天,给药5天停药2天,给药3周,延长观测1周。
(3)实验观察和数据采集
分组给药后,每周常规监测肿瘤对动物正常行为的影响。具体内容有实验动物的活动性,摄食和饮水情况,体重增加或降低情况,眼睛、被毛及其它异常情况。试验过程中观察到的临床症状均记录在原始数据中。
每周2次记录小鼠体重、肿瘤体积;
给药过程中小鼠若出现明显体重下降(低于分组时的90%)或其他异常情况,及时做好记录,必要时暂停给药并增加观察频率。
(4)非实验终点动物安乐标准
若药效实验结束前,肿瘤体积已大于2000mm3时,则提前对这些动物进行人道主义终点处理。
当小鼠体重下降超过20%的情况持续超过72小时,将对其实施安乐死。
其他动物安乐死标准:持续稀便、活动迟缓(不能进食或饮水)、弓背,侧卧;活动减少,出现肌肉萎缩症状;呼吸困难;进程性体温降低;瘫痪,痉挛;持续流血;由于严重的腹水或腹围增大导致动物不能够正常行动;
(5)实验终点
实验结束时,分析下列指标:A.肿瘤生长曲线;B.小鼠体重曲线;C.肿瘤重量;D.剥离的肿瘤按照组别进行排列后统一拍照。
(6)肿瘤保存方式:A.中性甲醛固定;B.低温速冻保存(-80℃保存)。
(7)统计分析
采用独立样本T检验比较各组有无显著性差异。P<0.05为具有显著性差异。
2、实验结果
利用HBV阳性肝癌PDX模型评估ATR抑制剂联合PARP1抑制剂疗效的结果如图1、表1和表2所示。
表1.各组HBV阳性肝癌PDX肿瘤体积随给药时间的变化
注:G1和G4肿瘤生长均较快,相比无显著性差异;而G2和G3均对肿瘤生长具有抑制作用,G3对肿瘤生长的抑制明显优于G2。其中,实验第28天,G1和G3、G2相比有显著性差异(P<0.05),G1和G4相比无显著性差异(P>0.05);G2和G3相比有显著性差异(P=0.0133);G3和G4相比有显著性差异(P<0.05)。
表2.各组给药28天后HBV阳性肝癌PDX肿瘤重量
由图1、表1和表2可知:单独使用PARP1抑制剂对HBV阳性肝癌没有抑制作用,即PARP1抑制剂不能治疗乙肝相关性肝癌;而ATR抑制剂和PARP1抑制剂联合使用后对HBV阳性肝癌有良好的抑制作用,效果优于单独使用ATR抑制剂。说明ATR抑制剂和PARP1抑制剂联合治疗HBV阳性肝癌发挥了协同增效的作用。
实施例2、利用HBV阴性肝癌PDX模型评估ATR抑制剂联合PARP1抑制剂的疗效
1、实验方法
(1)HBV阴性肝癌PDX模型的构造方法:建立肝癌PDX模型通过华西医院伦理委员会批准,选择HBV阴性肝癌组织,剪碎成绿豆大小,1小时内接种于NCG小鼠皮下,当肿瘤体积达到500mm3时,再次扩增传代至开展药效实验。
(2)药物评价方法:
按药效实验需要接种肿瘤组织至相应数量的NCG小鼠,当肿瘤体积平均值达到100mm3左右时,按照统计学方法进行随机分组,每组入组7只荷瘤鼠。具体分组及给药方法如下:
组别G1(溶剂对照组):荷瘤鼠只数为7只,同时给药溶媒1和溶媒2。溶媒1和溶媒2的给药体积分别100μL/只,给药方式为灌胃给药(i.g.)。
组别G2:荷瘤鼠只数为7只,给药ATR抑制剂AZD6738。将AZD6738溶于溶媒1中,AZD6738的给药剂量为50mg/kg,给药体积为100μL/只,给药方式为灌胃给药(i.g.)。
组别G3:荷瘤鼠只数为7只,ATR抑制剂AZD6738和PARP1抑制剂AG14361联合给药。将AZD6738溶于溶媒1中,AG14361溶于溶媒2中:AZD6738的给药剂量为50mg/kg,给药体积为100μL/只,给药方式为灌胃给药(i.g.);AG14361的给药剂量为15mg/kg,给药体积为100μL/只,给药方式为腹腔注射(i.p.)。
组别G4:荷瘤鼠只数为7只,给药PARP1抑制剂AG14361。将AG14361溶于溶媒2中,AG14361的给药剂量为15mg/kg,给药体积为100μL/只,给药方式为腹腔注射(i.p.)。
溶媒1:含二甲亚砜(DMSO)和丙二醇的ddH2O,其中二甲亚砜浓度为10%,丙二醇浓度为40%;溶媒2:含二甲亚砜(DMSO)的ddH2O,其中二甲亚砜浓度为4%;溶媒1和溶媒2配制好后均置于-80℃保存。
所有组给药频率为1次/天,给药5天停药2天,给药3周,延长观测1周。
(3)实验观察和数据采集
分组给药后,每周常规监测肿瘤对动物正常行为的影响。具体内容有实验动物的活动性,摄食和饮水情况,体重增加或降低情况,眼睛、被毛及其它异常情况。试验过程中观察到的临床症状均记录在原始数据中。
每周2次记录小鼠体重、肿瘤体积;
给药过程中小鼠若出现明显体重下降(低于分组时的90%)或其他异常情况,及时做好记录,必要时暂停给药并增加观察频率。
(4)非实验终点动物安乐标准
若药效实验结束前,肿瘤体积已大于2000mm3时,则提前对这些动物进行人道主义终点处理。
当小鼠体重下降超过20%的情况持续超过72小时,将对其实施安乐死。
其他动物安乐死标准:持续稀便、活动迟缓(不能进食或饮水)、弓背,侧卧;活动减少,出现肌肉萎缩症状;呼吸困难;进程性体温降低;瘫痪,痉挛;持续流血;由于严重的腹水或腹围增大导致动物不能够正常行动。
(5)实验终点
实验结束时,分析下列指标:A.肿瘤生长曲线;B.小鼠体重曲线;C.肿瘤重量;D.剥离的肿瘤按照组别进行排列后统一拍照。
(6)肿瘤保存方式:A.中性甲醛固定;B.低温速冻保存(-80℃保存)。
(7)统计分析
采用独立样本T检验比较各组有无显著性差异。P<0.05为具有显著性差异。
2、实验结果
利用HBV阴性肝癌PDX模型评估ATR抑制剂联合PARP1抑制剂疗效的结果如图2、表3和表4所示。
表3.各组HBV阴性肝癌PDX肿瘤体积随给药时间的变化
注:各组肿瘤体积无统计学差异(p=0.8230)。
表4.各组给药14天后HBV阴性肝癌PDX肿瘤重量
由图2、表3和表4可知:给药14天时对照组(G1)死亡7只,ATR单药组死亡2只;PRAP1单药组死亡6只,ATR抑制剂单用组及联合PARP1抑制剂组死亡2只,组间肿瘤大小无差异。可知ATR抑制剂、PARP1抑制剂无论单用还是联用,对HBV阴性肝癌均无明显抑制作用。
上述实验结果说明:ATR抑制剂和PARP1抑制剂联合使用仅仅对HBV阳性肝癌,即对乙肝相关性肝癌具有协同增效作用,对于非乙肝相关性肝癌具无协同增效的作用。
综上,ATR抑制剂和PARP1抑制剂联合使用能够有效抑制乙肝相关性肝癌的肿瘤组织生长,可有效治疗乙肝相关性肝癌;且联合使用ATR抑制剂和PARP1抑制剂对乙肝相关性肝癌具有协同增效的作用,可用于制备治疗乙肝相关性肝癌的药物,具有良好的前景。
Claims (10)
1.ATR抑制剂和PARP1抑制剂联用在制备治疗乙肝相关性肝癌的药物中的用途。
2.根据权利要求1所述的用途,其特征在于:所述ATR抑制剂和PARP1抑制剂的重量配比为(5~20):3;
优选地,所述ATR抑制剂和PARP1抑制剂的重量配比为10:3。
3.根据权利要求1或2所述的用途,其特征在于:所述ATR抑制剂为AZD6738;所述PARP1抑制剂为AG14361。
4.一种治疗乙肝相关性肝癌的药物组合物,其特征在于:它是由ATR抑制剂和PARP1抑制剂组成。
5.根据权利要求4所述的药物组合物,其特征在于:所述ATR抑制剂和PARP1抑制剂的重量配比为(5~20):3;
优选地,所述ATR抑制剂和PARP1抑制剂的重量配比为10:3。
6.根据权利要求4或5所述的药物组合物,其特征在于:所述ATR抑制剂为AZD6738;所述PARP1抑制剂为AG14361。
7.一种权利要求4~6任一项所述的药物组合物的制备方法,其特征在于:所述方法是按照以下步骤制备:按照重量配比取ATR抑制剂和PARP1抑制剂,混合,即可。
8.一种治疗乙肝相关性肝癌的药物制剂,其特征在于:它是由权利要求4~6任一项所述的药物组合物为活性成分,加上药学上可接受的辅料或者辅助性成分制备而成的制剂。
9.一种治疗乙肝相关性肝癌的联合用药,其特征在于:它含有相同或者不同规格的同时或者分别给药的ATR抑制剂和PARP1抑制剂,以及药学上可接受的载体;所述ATR抑制剂和PARP1抑制剂的重量配比为(5~20):3;
优选地,所述ATR抑制剂和PARP1抑制剂的重量配比为10:3。
10.根据权利要求9所述的联合用药,其特征在于:所述ATR抑制剂为AZD6738;所述PARP1抑制剂为AG14361。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010536991.0A CN113797341B (zh) | 2020-06-12 | 2020-06-12 | Atr抑制剂和parp1抑制剂联用在制备治疗乙肝相关性肝癌的药物中的用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN202010536991.0A CN113797341B (zh) | 2020-06-12 | 2020-06-12 | Atr抑制剂和parp1抑制剂联用在制备治疗乙肝相关性肝癌的药物中的用途 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN113797341A true CN113797341A (zh) | 2021-12-17 |
CN113797341B CN113797341B (zh) | 2022-11-11 |
Family
ID=78892177
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN202010536991.0A Active CN113797341B (zh) | 2020-06-12 | 2020-06-12 | Atr抑制剂和parp1抑制剂联用在制备治疗乙肝相关性肝癌的药物中的用途 |
Country Status (1)
Country | Link |
---|---|
CN (1) | CN113797341B (zh) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023242302A1 (en) * | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN109512822A (zh) * | 2018-12-25 | 2019-03-26 | 同济大学 | 一种治疗肝癌的联合药物组合物 |
WO2020049309A1 (en) * | 2018-09-06 | 2020-03-12 | Cycle Pharmaceuticals Ltd | 5-acetamidomethyl-oxazolidinone derivatives for use in the treatment of cancer |
-
2020
- 2020-06-12 CN CN202010536991.0A patent/CN113797341B/zh active Active
Patent Citations (2)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2020049309A1 (en) * | 2018-09-06 | 2020-03-12 | Cycle Pharmaceuticals Ltd | 5-acetamidomethyl-oxazolidinone derivatives for use in the treatment of cancer |
CN109512822A (zh) * | 2018-12-25 | 2019-03-26 | 同济大学 | 一种治疗肝癌的联合药物组合物 |
Non-Patent Citations (1)
Title |
---|
LLOYD, RL ET AL ,: "Combined PARP and ATR inhibition potentiates genome instability and cell death in ATM-deficient cancer cells,", 《ONCOGENE》 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2023242302A1 (en) * | 2022-06-15 | 2023-12-21 | Astrazeneca Ab | Combination therapy for treating cancer |
Also Published As
Publication number | Publication date |
---|---|
CN113797341B (zh) | 2022-11-11 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
McCann et al. | Advances in the use of PARP inhibitor therapy for breast cancer | |
US11406643B2 (en) | Targeting kinases for the treatment of cancer metastasis | |
CN110934873B (zh) | 靶向组织微环境中衰老细胞的抗衰老药物d/s及其应用 | |
CN107207471B (zh) | 用于治疗神经母细胞瘤的组合 | |
WO2016123054A2 (en) | Kinase drug combinations and methods of use thereof | |
CN101842095A (zh) | 肿瘤治疗的配方,方法和靶目标 | |
US11576919B2 (en) | Treatment of breast cancer using combination therapies comprising an ATP competitive AKT inhibitor, a CDK4/6 inhibitor, and fulvestrant | |
Chen et al. | Novel PI3K/Akt/mTOR pathway inhibitors plus radiotherapy: strategy for non-small cell lung cancer with mutant RAS gene | |
Phelps et al. | Inhibition of MDM2 by RG7388 confers hypersensitivity to X‐radiation in xenograft models of childhood sarcoma | |
Quispe et al. | Focal adhesion kinase inhibitors in the treatment of solid tumors: Preclinical and clinical evidence | |
Bhoopathi et al. | The quest to develop an effective therapy for neuroblastoma | |
WO2020056188A1 (en) | Combination of parp inhibitor and brd4 inhibitor for the treatment of cancer | |
Nan et al. | Imatinib revives the therapeutic potential of metformin on ewing sarcoma by attenuating tumor hypoxic response and inhibiting convergent signaling pathways | |
Stone | Which new agents will be incorporated into frontline therapy in acute myeloid leukemia? | |
Chalmers | Radioresistant glioma stem cells—therapeutic obstacle or promising target? | |
CN113797341B (zh) | Atr抑制剂和parp1抑制剂联用在制备治疗乙肝相关性肝癌的药物中的用途 | |
WO2023272831A1 (zh) | 水苏糖在制备用于治疗去势抵抗性前列腺癌药物中的应用 | |
Kong et al. | Modified Bushen Yiqi formula enhances antitumor immunity by reducing the chemotactic recruitment of M2-TAMs and PMN-MDSCs in Lewis lung cancer-bearing mice | |
US9808469B2 (en) | Antitumor activity of multi-kinase inhibitors in triple negative breast cancer | |
Stern et al. | Chemotherapy in the treatment of malignant gliomas | |
Stockwin et al. | ARC (NSC 188491) has identical activity to Sangivamycin (NSC 65346) including inhibition of both P-TEFb and PKC | |
EP4279489A1 (en) | Application of pyrido[1,2-a]pyrimidinone analog | |
RU2516027C2 (ru) | Комбинация противораковых агентов | |
Leighl et al. | A phase I/II study of GTI-2040 plus docetaxel as second-line treatment in advanced non-small cell lung cancer: a study of the PMH phase II consortium | |
AU2020224164A1 (en) | GMCI and DDRI combination therapy for treating cancer |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right |
Effective date of registration: 20230524 Address after: No.37 Guoxue lane, Wuhou District, Chengdu, Sichuan 610044 Patentee after: WEST CHINA HOSPITAL OF SICHUAN University Address before: No.211, unit 1, building 2, No.5 Jing'an Road, Jinjiang District, Chengdu, Sichuan 610000 Patentee before: Zhou Lingyun |
|
TR01 | Transfer of patent right |